Rogliani Paola, Chetta Alfredo, Cazzola Mario, Calzetta Luigino
Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Vaccines (Basel). 2021 Mar 5;9(3):227. doi: 10.3390/vaccines9030227.
: There are no studies providing head-to-head comparison across SARS-CoV-2 vaccines. Therefore, we compared the efficacy of candidate vaccines in inducing neutralizing antibodies against SARS-CoV-2. : A network meta-analysis was performed to compare the peak levels of SARS-CoV-2 neutralizing antibodies across candidate vaccines. Data were reported as standardized mean difference (SMD) since the outcome was assessed via different metrics and methods across the studies. : Data obtained from 836 healthy adult vaccine recipients were extracted from 11 studies. BBIBP-CorV, AZD1222, BNT162b2, New Crown COVID-19, and Sputnik V induced a very large effect on the level of neutralizing antibodies (SMD > 1.3); CoVLP, CoronaVac, NVX-CoV2373, and Ad5-nCoV induced a large effect (SMD > 0.8 to ≤1.3); and Ad26.COV2.S induced a medium effect (SMD > 0.5 to ≤0.8). BBIBP-CorV and AZD122 were more effective ( < 0.05) than Ad26.COV2.S, Ad5-nCoV, mRNA-1237, CoronaVac, NVX-CoV2373, CoVLP, and New Crown COVID-19; New Crown COVID-19 was more effective ( < 0.05) than Ad26.COV2.S, Ad5-nCoV, and mRNA-1237; CoronaVac was more effective ( < 0.05) than Ad26.COV2.S and Ad5-nCoV; and Sputnik V and BNT162b2 were more effective ( < 0.05) than Ad26.COV2.S. In recipients aged ≤60 years, AZD1222, BBIBP-CorV, and mRNA-1237 were the most effective candidate vaccines. : All the candidate vaccines induced significant levels of SARS-CoV-2 neutralizing antibodies, but only AZD1222 and mRNA-1237 were certainly tested in patients aged ≥70 years. Compared with AZD1222, BNT162b and mRNA-1237 have the advantage that they can be quickly re-engineered to mimic new mutations of SARS-CoV-2.
目前尚无关于不同新冠病毒疫苗进行直接对比的研究。因此，我们比较了候选疫苗诱导针对新冠病毒的中和抗体的效力。：进行了一项网状Meta分析，以比较不同候选疫苗诱导的新冠病毒中和抗体峰值水平。由于各项研究中该结果是通过不同指标和方法评估的，数据以标准化均值差（SMD）形式呈现。：从11项研究中提取了836名健康成年疫苗接种者的数据。BBIBP-CorV、AZD1222、BNT162b2、新型冠状病毒肺炎疫苗、卫星V疫苗对中和抗体水平有非常大的影响（SMD>1.3）；CoVLP、科兴新冠疫苗、NVX-CoV2373、Ad5-nCoV有较大影响（SMD>0.8至≤1.3）；Ad26.COV2.S有中等影响（SMD>0.5至≤0.8）。BBIBP-CorV和AZD1222比Ad26.COV2.S、Ad5-nCoV、mRNA-1237、科兴新冠疫苗、NVX-CoV2373、CoVLP、新型冠状病毒肺炎疫苗更有效（P<0.05）；新型冠状病毒肺炎疫苗比Ad26.COV2.S、Ad5-nCoV和mRNA-1237更有效（P<0.05）；科兴新冠疫苗比Ad26.COV2.S和Ad5-nCoV更有效（P<0.05）；卫星V疫苗和BNT162b2比Ad26.COV2.S更有效（P<0.05）。在60岁及以下的接种者中，AZD1222、BBIBP-CorV和mRNA-1237是最有效的候选疫苗。：所有候选疫苗均诱导产生了显著水平的新冠病毒中和抗体，但只有AZD1222和mRNA-1237在70岁及以上患者中进行了确切测试。与AZD1222相比，BNT162b和mRNA-1237的优势在于它们可以快速重新设计以模拟新冠病毒的新突变。
